Contents
In the Medtronic 2011 study registry settlement, Medtronic agreed to pay $23.5 million to resolve allegations that it used research payments as kickbacks for pacemaker and defibrillator business. For someone in clinical research or medical device sales, the revealing detail is how Medtronic recruited physicians. The government alleged that Medtronic sought doctors whose business it could take from a competitor or keep for itself.
The Justice Department announced the settlement on December 12, 2011. Its account connected physician payments to medical device selection and then to allegedly false Medicare and Medicaid claims.
According to the Justice Department’s allegations, Medtronic paid participating physicians approximately $1,000 to $2,000 per patient through two post-market studies and two medical device registries. Those programs required a new or previous Medtronic implant in every patient.
A post-market study assesses how a medical device performs after Food and Drug Administration approval. A registry holds a manufacturer’s data about products sold and implanted in patients. Both put the physician’s experience with a medical device into a form the manufacturer can collect and examine.
Medtronic did collect data from the physicians, the government acknowledged. It also alleged that the company used the studies and registries to induce doctors to implant its products. The same arrangement could produce a research record and serve a sales objective.
Recruitment is the detail that gives that allegation its commercial meaning. According to the government, Medtronic solicited physicians to switch their business from competing products or continue using Medtronic medical devices. A previous implant could satisfy the enrollment requirement, while retaining the physician’s future business remained an alleged purpose of the payment.
A 2020 review in the Journal of Forensic and Investigative Accounting, A Forensic Accountant’s Guide to the Most Potent Federal Laws Used Against Healthcare Fraud, explains that a payment can serve another purpose and still be intended to induce future referrals. Applied to Medtronic’s alleged arrangement, that distinction puts the recruitment decision alongside the completed study forms: what business did the company want from the physician?
A payment to a physician could influence a purchase made by the institution. The government alleged that the study and registry payments induced Medtronic implants and caused false healthcare claims to reach Medicare and Medicaid.
The bill alone can leave much of that connection invisible. A hospital claim may identify a defibrillator implantation without identifying the particular model implanted. The research enrollment, physician payment and product choice sit in records outside that claim. An insider who knows why a physician was recruited can explain something the payer cannot see by reading the procedure on the bill.
Patients depend on the physician’s judgment about what belongs in their bodies. The Justice Department’s stated concern was that financial incentives distorted that judgment, with taxpayers funding the resulting health care. Competitors stood to lose business when Medtronic allegedly paid physicians to switch products. The Justice Department described the Anti-Kickback Law’s purpose here as keeping unlawful payments out of medical judgment.
Yes. This settlement resolved allegations in two whistleblower lawsuits under the False Claims Act, one in Minnesota and one in California.
The Justice Department announced that the whistleblowers would receive payments totaling more than $3.96 million from the federal share of the recovery.
A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.
St. Jude Medical also settled allegations that it used study and registry payments to induce physicians to select its pacemakers and defibrillators.
For study and registry payment allegations, the evidence connects the terms of the physician’s compensation, the medical device business sought in return and the resulting government claim. Enrollment requirements explain which patients qualified for a payment. Recruitment communications can explain why the company wanted a particular physician in the study. Implant and purchasing records connect that physician’s decisions to the products used in patient care.
Those records may sit with different people. A clinical research employee may know the enrollment terms and data actually collected. Someone in sales may know which physicians the company wanted to convert or retain. Hospital staff may know the implant used and the claim submitted. We work with the insider to connect those views into an account of the payment, the decision and the bill.
If you saw research payments tied to winning or keeping medical device business, speak to our whistleblower experts about building your strongest medical device fraud case. We build the case with you, bring in medical device fraud whistleblower lawyers who understand physician payments and hospital claims, and stay beside you throughout the case.